touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022.
Questions
- What are the hopes of the new drug delivery mechanism using L-asparaginase to treat advanced pancreatic cancer? 00:15-01:13
- Why did the TRYbeCA-1 study fail to meet its primary endpoint? 01:13-02:53
- How have KRAS G12C inhibitors impacted clinical practice? 02:53-04:33
- What can you conclude from the updated results from the KRYSTAL-1 trial in KRAS G12C+ gastrointestinal cancers Cancers? 04:33-06:13
- How do you see the future for drug development in advanced pancreatic cancer? 06:14-08:19
Speaker Disclosure: Benjamin A Weinberg has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.
